SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Portfolio Pulse from
SPRAVATO® (esketamine) has been approved by the U.S. FDA as the first and only monotherapy for adults with treatment-resistant depression. The approval follows a Priority Review and is based on data showing rapid and superior improvement in depressive symptoms compared to placebo.
January 21, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's SPRAVATO® has been approved by the FDA as the first monotherapy for treatment-resistant depression, showing rapid improvement in symptoms.
The FDA approval of SPRAVATO® as a monotherapy for treatment-resistant depression is a significant milestone for Johnson & Johnson. This approval could lead to increased sales and market share in the depression treatment market, positively impacting JNJ's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90